---
title: "In the performance report, EVEREST MED's annual loss narrowed to 298 million RMB, and no dividend will be distributed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280546355.md"
description: "EVEREST MED announced its full-year results for the year ended December last year, with a revenue of RMB 1.707 billion, an increase of 141.5% year-on-year. The loss narrowed to RMB 298 million, compared to a loss of RMB 1.041 billion in the same period last year; the loss per share was RMB 0.89. No dividend was declared"
datetime: "2026-03-26T00:55:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280546355.md)
  - [en](https://longbridge.com/en/news/280546355.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280546355.md)
---

# In the performance report, EVEREST MED's annual loss narrowed to 298 million RMB, and no dividend will be distributed

EVEREST MED (01952.HK) announced its full-year results for the year ended December last year, with a revenue of RMB 1.707 billion, an increase of 141.5% year-on-year. The loss narrowed to RMB 298 million, compared to a loss of RMB 1.041 billion in the same period last year; the loss per share was RMB 0.89. No dividend was declared

### Related Stocks

- [01952.HK](https://longbridge.com/en/quote/01952.HK.md)

## Related News & Research

- [Tesla surpasses 10 billion FSD miles, is unsupervised near?](https://longbridge.com/en/news/285084404.md)
- [Atari Acquires Rights to the Legendary Wizardry RPGs | PONGD Stock News](https://longbridge.com/en/news/285456726.md)
- [Invitation to the Presentation of Cantargia's Interim Report for Q1 2026](https://longbridge.com/en/news/285339581.md)
- [Canaccord Genuity Initiates a Buy Rating on Kraken Robotics Systems Inc (PNG)](https://longbridge.com/en/news/285277387.md)
- [<![CDATA[FDA Clears Investigational New Drug Application for Phase Ib/IIa Trial of CK0802 in Steroid-Refractory Graft-Versus-Host Disease]]>](https://longbridge.com/en/news/285251535.md)